

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p align="center">Licensee</p> <p>1. Terre Haute Regional Hospital</p> <p>2. 3901 South 7th Street Terre Haute, IN 47802</p>	<p>In accordance with letter dated August 29, 2013,</p> <p>3. License number 13-09649-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date June 30, 2021</p> <hr/> <p>5. Docket No. 030-09540 Reference No.</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Palladium-103, permitted by 10 CFR 35.400</p> <p>E. Iodine-125, permitted by 10 CFR 35.400</p> <p>F. Iridium-192, permitted by 10 CFR 35.400</p> <p>G. Cesium-137, permitted by 10 CFR 35.400</p> <p>H. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Best Medical International, Inc., Model 2335; Theragenics Corporation TheraSeed Model 200)</p> <p>E. Sealed Sources (Medi-Physics, Inc., Model 6711 (OncoSeed™); Theragenics Corporation I-Seed Model AgX100)</p> <p>F. Sealed Sources (Best Medical International, Inc., Model 81-01)</p> <p>G. Sealed Sources (3M Health Physics Service Model 6500 Series and 6520 Series (together formerly Model 6D6C source); AEA Technology Model CDC.T1)</p> <p>H. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. One curie</p> <p>D. One curie</p> <p>E. One curie</p> <p>F. One curie</p> <p>G. One curie</p> <p>H. Two millicuries</p>

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-09649-02Docket or Reference Number
030-09540**Amendment No. 64**
Corrected Copy

- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. through G. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- H. In vitro studies.

CONDITIONS

10. A. Licensed material may be used only at the licensee's facilities located at 3901 South 7th Street, Terre Haute, Indiana.
- B. Licensed material listed in Subitem Nos. 6.A., 6.B., and 6.C., may also be used at the licensee's facilities located at 135 East McCallister Drive, Terre Haute, Indiana.
11. The Radiation Safety Officer for this license is Edward Johnston III.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Edward R. Bartley, M.D.

10 CFR 35.100 and 35.200.

Jack M. Drew, M.D.

10 CFR 35.100, 35.200, and 35.300.

Eric D. Elliott, M.D.

10 CFR 35.100 and 35.200.

Steven A. Fritsch, M.D.

10 CFR 35.100 and 35.200.

John A. Morton, M.D.

10 CFR 35.100, 35.200, 35.300, and 31.11.

Brian J. Wiegel, M.D.

10 CFR 35.100, 35.200, and 35.300.

Peter D. Arken, M.D.

10 CFR 35.100, 35.200, and 35.300.

Homer F. Beltz, M.D.

10 CFR 35.100 and 35.200.

Theodore P. Labus, M.D.

10 CFR 35.100, 35.200, and 35.300.

Charles A. Lerner, M.D.

10 CFR 35.100 and 35.200.

Michael S. Skulski, M.D.

10 CFR 35.100 and 35.200.

Margaret Brengle, M.D.

10 CFR 35.100 and 35.200.

Jeffrey I. Reider, M.D.

10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-09649-02Docket or Reference Number
030-09540**Amendment No. 64**
Corrected CopyAuthorized Users

Janalyn P. Ferguson, M.D.

Jack J. Moss, M.D.

Lori J. Wells, M.D.

Thomas Hagman, M.D.

J. Michael Phelps, Jr. M.D.

Timothy L. Davis, M.D.

Vincent P. Mathews, M.D.

William E. McGraw, M.D.

John Mark Michael, M.D.

Frank J. Pistoia, M.D.

Cristina N. Shinaver, M.D.

Richard L. Hallet, M.D.

Caryn Cockerill Anderson, M.D.

Warren Kent Hansen, M.D.

Carlo Roberto Lazzaro, M.D.

Jane S. Mitchell, M.D.

David R. Gulliver, M.D.

Thomas M. Schmitz, M.D.

Jonathan Kahn, M.D.

Laura Dugan, M.D.

Ryan N. Sauer, M.D.

Larry L. Stover, M.D.

Material and Use

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

10 CFR 35.100 and 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.300 and 35.400.

10 CFR 35.100, 35.200, and 35.300.

10 CFR 35.100 and 35.200.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-09649-02Docket or Reference Number
030-09540**Amendment No. 64**
Corrected CopyAuthorized Users

Kelly K. Horst, M.D.

Eric E. Beltz, M.D.

Kavita K. Erickson, M.D.

Material and Use

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).


10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).**10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131, to the parenteral administration of any beta emitter, and to the parenteral administration of any photon-emitting radionuclide with a photon energy less than 150 keV).**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated **February 2, 2011**, with attached application dated **February 2, 2011**.
- B. Letter received on April 11, 2013 (dated April 2, 2012).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 19 2014

By

Sara A.B. Forster, M.S.
Materials Licensing Branch
Region III